ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2729

Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome

Hasan Tuzun1, Gul Guzelant2, Ozkan Demirhan3, Buge Oz4, Izzet Fresko2, Vedat Hamuryudan2, Hasan Yazici2 and Emire Seyahi2, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiovascular Surgery, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Istanbul Bilim University, Medical Faculty, Department of Thoracic Surgery, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Behcet's syndrome, Pulmonary Involvement and surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the management of PAI can be questionable in many cases considering the severe outcome of our previous attempts (2-3). For the past few years we observed that there are indeed several conditions associated with PAI which require surgical operations.   In this study, we described disease characteristics, management and outcome of a group of BS patients who underwent surgical procedures for complications due to PAI.

Methods: There were 9 patients with BS (8 M/1 F) who underwent surgery for PAI from 2003 to 2016 at the Department of Thoracic and Cardiovascular Surgery, Cerrahpaþa Medical Faculty. The medical records, outpatient charts, radiological and pathological studies of these patients were reviewed retrospectively.

Results: The mean age of the patients was 24.8± 7.5 years (range: 12-35). The mean duration of the disease at the time of the surgery was 4.3±3.8 years. The main symptom was haemoptysis. The most common surgery type was lobectomy which was done in 6 patients, followed by decortications in 3. The reason for the surgical procedures were variable as shown in Table. It was giant pulmonary arterial aneurysms refractory to the medical treatment in 4 patients (patients no.  1, 2, 3 and 4), hydropneumothorax due to cavitary lesions in two (patients no. 5 and 6), pleural effusions refractory to the medical treatment in one (patient no. 7), bronchopleural fistula after embolization in one (patient no. 8) and bronchiectasis in another (patient no. 9).  All patients received cyclophosphamide treatment with different total doses. Seven patients (patient no. 2, 4, 5, 6, 7, 8 and 9) are still alive and are being followed in our clinic for a median of 7.5 years (IQR:1.5-11).  Patient no. 1 had died because of hepatic failure due to Budd-Chiari syndrome after 1 year from the surgery and patient no. 3 had died because of massive haemoptysis within 2 months of lobectomy. 

Conclusion: We now think that lobectomies in patients with giant aneurysms refractory to medical treatment can be done with successful results. Also, complications such as refractory pleural effusions, bronchiectasies and broncopleural fistula can be managed with surgical interventions successfully in patients with PAI. 

References:

1-      Seyahi E et al. Medicine (Baltimore). 2012.

2-      Tüzün H et al. Ann Thorac Surg. 1996.

3-      Hamuryudan V et al. Br J Rheumatol. 1994. 

Table. Main symptom and type of surgical intervention in 9 patients

Patient no.

Age

Presentation

Preoperative treatment

Surgical procedure

1

12

Haemoptysis

Cyclophosphamide 1.5 gr

Left lower lobectomy

2

21

Haemoptysis

Cyclophosphamide 3 gr, infliximab 300 mg (first dose)

Right lower lobectomy

3

16

Haemoptysis

Cyclophosphamide 2 gr

Left lower lobectomy

4

28

Haemoptysis

Cyclophosphamide 1 gr

Right lower lobectomy

5

28

Hydropneumothorax

Cyclophosphamide 6 gr

Left lower lobectomy and decortications

6

23

Hydropneumothorax

Cyclophosphamide 8 gr

Capitonnage

7

29

Empyema

Cyclophosphamide 12 gr, after than azathioprine

Decortication and wedge resection

8

32

Empyema

Cyclophosphamide 2 gr

Decortication

9

35

Haemoptysis

Cyclophosphamide 7 gr, after than azathioprine

Left lower lobectomy


Disclosure: H. Tuzun, None; G. Guzelant, None; O. Demirhan, None; B. Oz, None; I. Fresko, None; V. Hamuryudan, None; H. Yazici, None; E. Seyahi, None.

To cite this abstract in AMA style:

Tuzun H, Guzelant G, Demirhan O, Oz B, Fresko I, Hamuryudan V, Yazici H, Seyahi E. Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/surgical-therapies-in-the-treatment-of-pulmonary-artery-involvement-in-behcets-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/surgical-therapies-in-the-treatment-of-pulmonary-artery-involvement-in-behcets-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology